Sonoma Pharmaceuticals (SNOA) Liabilities and Shareholders Equity (2011 - 2026)

Sonoma Pharmaceuticals' Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $14.0 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 1.95% year-over-year to $14.0 million in Q1 2026; TTM through Mar 2026 was $56.0 million, a 2.4% increase from a year earlier, with the FY2026 full-year figure at $14.0 million, up 1.95% from the prior year.
• Liabilities and Shareholders Equity improved to $14.0 million in Q1 2026 per SNOA's latest filing, from $13.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $18.8 million in Q1 2022 and bottomed at $13.6 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $14.0 million (2026), against an average of $14.8 million.
• Biggest YoY gain for Liabilities and Shareholders Equity was 25.74% in 2022; the steepest drop was 28.01% in 2022.
• Year by year, Liabilities and Shareholders Equity stood at $13.9 million in 2022, then grew by 4.95% to $14.6 million in 2023, then slipped by 6.5% to $13.7 million in 2024, then decreased by 0.33% to $13.6 million in 2025, then increased by 2.47% to $14.0 million in 2026.
• Per Business Quant, the three latest SNOA Liabilities and Shareholders Equity figures stand at $14.0 million (Q1 2026), $13.6 million (Q4 2025), and $13.9 million (Q3 2025).